Cargando…
Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status
BACKGROUND: BRCA1/2 mutations lead to an elevated risk of breast cancer. None involved in whether BRCA1/2 mutation status will affect the first decision-making of sentinel lymph node (SLN) biopsy or not for clinically node-negative breast cancer. We retrospectively investigated whether BRCA1/2 mutat...
Autores principales: | Huang, Xin, Liu, Jia-Qi, Zhou, Yi-Dong, Xu, Ying, Chen, Chang, Wang, Xiang, Cao, Xi, Yao, Ru, Sun, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576024/ https://www.ncbi.nlm.nih.gov/pubmed/33241032 http://dx.doi.org/10.21037/atm-20-5996 |
Ejemplares similares
-
Status of Sentinel Lymph Node Biopsy in Gynecological Cancers
por: Levenback, Charles F.
Publicado: (2007) -
Status of Sentinel Lymph Node Biopsy in Endometrial Cancer
por: Taran, Florin Andrei, et al.
Publicado: (2021) -
Imprint Cytology Predicts Axillary Node Status in Sentinel Lymph Node Biopsy
por: Bell, Zarina, et al.
Publicado: (2010) -
Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma
por: Falk Delgado, Alberto, et al.
Publicado: (2019) -
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy
por: Adler, Nikki R., et al.
Publicado: (2018)